Medicine and Dentistry
Radiation Therapy
100%
Neoplasm
74%
Glioblastoma
72%
Brain Metastasis
67%
Stereotactic Radiosurgery
52%
Chemoradiotherapy
35%
Metastatic Carcinoma
34%
Magnetic Resonance Imaging
32%
Stereotactic Body Radiation Therapy
31%
Esophageal Cancer
29%
Surgery
28%
Adenocarcinoma
26%
Disease
26%
Oncology
25%
Ganglioglioma
24%
Malignant Neoplasm
23%
Recurrent Disease
22%
Systemic Therapy
22%
Overall Survival
19%
Radiosurgery
19%
Cisplatin
19%
Clinical Trial
19%
Intensity Modulated Radiation Therapy
17%
Spine Metastasis
17%
Stomach Cancer
16%
Stereotactic Radiotherapy
16%
Temozolomide
15%
Esophagus
14%
Tumor Progression
14%
Gastroesophageal Junction
14%
Survival Rate
13%
Biological Marker
12%
Brain Radiation
12%
Brain Tumor
12%
Tumor Recurrence
12%
Drug Megadose
12%
Nodular Melanoma
12%
Whole Brain Radiotherapy
11%
Immune Checkpoint Inhibitor
11%
Radiation Necrosis
11%
Lymphocytopenia
10%
Vestibular Schwannoma
10%
Tumor Treating Fields
9%
Neural Stem Cell
9%
Esophagectomy
9%
Fluorouracil
9%
Brachytherapy
9%
Carmustine
9%
Prognostic Factor
8%
Clear Cell Renal Cell Carcinoma
8%
Keyphrases
Brain Metastases
54%
Stereotactic Radiosurgery
45%
Glioblastoma
36%
Radiation Therapy
33%
Radiotherapy
29%
Tumor
28%
Newly Diagnosed Glioblastoma
23%
Radiosurgery
20%
Esophageal Cancer
19%
Phase II Study
17%
Systemic Therapy
17%
Spectroscopic MRI
17%
Newly Diagnosed
16%
Magnetic Resonance Imaging
16%
Chemotherapy
16%
Temozolomide
14%
Local Control
14%
Tumor Progression
13%
Recurrence Pattern
13%
High-grade Glioma
12%
Overall Survival
12%
Karnofsky Performance Status
11%
Immune Checkpoint Inhibitors
11%
Pathological Complete Response
11%
Survival Outcomes
11%
Chemoradiation
11%
Multi-institutional
10%
Vestibular Schwannoma
10%
Clinical Trials
10%
Glioblastoma multiforme
10%
Whole Brain Radiation Therapy
10%
Stereotactic Body Radiotherapy
10%
Stereotactic Radiotherapy
9%
Tumor Treating Fields
9%
MRI-guided
9%
Concurrent Chemoradiotherapy
9%
Gastroesophageal Junction Cancer
9%
Gastric Cancer
9%
Cisplatin
9%
Stereotactic Body Radiation Therapy
9%
Malignant Glioma
9%
Radiation Dose
9%
Radionecrosis
9%
Adenocarcinoma
9%
Neoadjuvant Chemoradiotherapy (nCRT)
9%
Radiation Necrosis
9%
Metastatic Disease
9%
Solid Tumors
9%
T1-weighted
9%
Esophageal Squamous Cell Carcinoma
8%